ESMO

Mündlicher Kurzvortrag: MCLA-129 in combination with osimertinib in treatment naïve, and after progression on osimertinib, non-small cell lung cancer (MCLA-129 in Kombination mit Osimertinib bei therapienaivem nicht-kleinzelligem…

HOUSTON, July 28, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the acceptance of two abstracts…

BERKELEY, Calif. and MAINZ, Germany, June 28, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in early cancer detection, is thrilled to…

<!-- Name:DistributionId Value:8754743 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:9530 -->…

-   Median overall survival (mOS) was numerically longer for patients receiving ZEJULA regardless of biomarker status, at 46.3 months compared to 43.4 months in the placebo group-   No new safety issues were identified SHANGHAI, China and…

- INNATE trial Phase 1 dose escalation data showed JTX-8064 was well-tolerated as a single agent and in combination with pimivalimab (pimi) - - Patient with advanced biliary tract cancer who failed multiple lines of prior treatment…

- Durable partial response (PR) and stable disease (SD) achieved in heavily pre-treated non-small cell lung cancer (NSCLC) patients dosed with cNeT monotherapy - - Updated interim Phase I/II results show encouraging safety and…

Data show an early signal of efficacy in an extensively pre-treated population with 1 complete response and 2 partial responses achieved in 14 evaluable patientsResponses achieved in patients with 3 distinct and different KRAS mutations,…

Currently used cisplatin-based combination treatments have limited efficacy against mesothelioma, which is one of the deadliest solid cancers Combining cisplatin with Allocetra™ led to a substantial and statistically significant survival…

REDWOOD CITY, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company developing innovative therapeutics in oncology, including targeting the colony-stimulating factor 1…